Prognostic Significance of Tissue Transglutaminase in Drug Resistant and Metastatic Breast Cancer
Authors:
- 1 December 2004
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 10 (23) , 8068-8076
Abstract
Purpose: Drug resistance and metastasis pose major impediments in the successful treatment of cancer. We previously reported that multidrug-resistant breast cancer cells exhibit high levels of tissue transglutaminase (TG2; EC 2.3.2.13). Because the drug-resistant and metastatic phenotypes are thought to share some common pathways, we sought to determine whether metastatic breast cancer cells express high levels of TG2. Experimental Design: The metastatic breast cancer cell line MDA-MB-231 and the sublines derived from it were tested for TG2 expression. Similarly, several sublines derived from an immortal but normal breast epithelial cell line, MCF10A, representing various stages in breast cancer progression were studied for TG2 expression. The primary and nodal tumor samples from 30 patients with breast cancer were also studied for TG2 expression. Results: The MDA-MB-231 cells expressed high basal levels of TG2. Two clones derived from this cell line, MDA231/cl.9 and MDA231/cl.16, showed a 10- to 15-fold difference in TG2 level. TG2-deficient MDA231/cl.9 cells exhibited higher sensitivity to doxorubicin and were less invasive than were the TG2-sufficient MDA231/cl.16 cells. The MCF10A-derived sublines had increased TG2 expression as they advanced from noninvasive to an invasive phenotype. Importantly, the metastatic lymph node tumors from patients with breast cancer showed significant higher levels of TG2 expression compared with the primary tumors from the same patients. Conclusions: TG2 expression is up-regulated in drug-resistant and metastatic breast cancer cells, and it can serve as a valuable prognostic marker for these phenotypes.Keywords
This publication has 41 references indexed in Scilit:
- Drug‐resistant breast carcinoma (MCF‐7) cells are paradoxically sensitive to apoptosisJournal of Cellular Physiology, 2004
- Transglutaminases: crosslinking enzymes with pleiotropic functionsNature Reviews Molecular Cell Biology, 2003
- Death and anti-death: tumour resistance to apoptosisNature Reviews Cancer, 2002
- RETRACTED ARTICLE: Suppression of matrix metalloproteinase-2 gene expression and invasion in human glioma cells by MMAC/PTENOncogene, 2001
- Integrin signaling inhibits paclitaxel-induced apoptosis in breast cancer cellsOncogene, 2001
- New aspects of integrin signaling in cancerSeminars in Cancer Biology, 2000
- Transglutaminase induction by various cell death and apoptosis pathwaysCellular and Molecular Life Sciences, 1996
- Clinical multidrug resistance in cancer: A multifactorial problemEuropean Journal of Cancer, 1996
- Intrinsic or acquired drug resistance and metastasis: Are they linked phenotypes?Journal of Cellular Biochemistry, 1994
- Molecular and cellular analysis of basement membrane invasion by human breast cancer cells in Matrigel-basedin vitro assaysBreast Cancer Research and Treatment, 1993